|Articles|March 15, 2007
Once-daily drug as safe as original formula
Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Physician perspective: Glaucoma eye drops are here to stay
2
American College of Physicians Calls for An End of the Term 'Provider' in Policy Paper
3
SparingVision completes PRODYGY trial patient dosing with SPVN06
4
PRIMA System: A major step in the battle against GA
5
























